-

Iambic to Participate in March Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven drug discovery platform, today announced its participation in upcoming March investor conferences:

  • Leerink Global Healthcare Conference: March 9-12
  • Jeffries Biotech Summit: March 10-11
  • KeyBanc Healthcare Forum: March 18-19

About Iambic

Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, internally and with partners, to address urgent unmet patient need as well as providing access to its industry-leading technology. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai

Contacts

media@iambic.ai

Industry:

Iambic

Release Versions
English

Contacts

media@iambic.ai

More News From Iambic

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with Takeda that will use Iambic’s industry leading AI drug discovery models to advance a select set of high-priority small molecule programs, initially in Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas....

Iambic Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life sciences and technology company advancing novel medicines through its AI-driven discovery and development platform, today announced that Tom Miller, Ph.D. (Co-Founder and Chief Executive Officer) and Fred Manby, Ph.D. (Co-Founder and Chief Technology Officer) will present at the 44th Annual J.P. Morgan Healthcare Conference. Iambic’s presentation will take place on Tuesday, January 13, 2026, at 4:30 p.m. PT at the Westin St. Francis Hote...

Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar In...
Back to Newsroom